Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>Soligenix, Inc. (SNGX) has a number of important catalysts ahead in the second half of 2025.</li><li>The company is currently conducting the Phase 3 FLASH2 trial of HyBryte (SGX301) for the treatment of early-stage cutaneous T cell lymphoma (CTCL).</li><li>We anticipate an update on enrollment in the 2H25, with topline results expected in the 2H26.</li></ul>

Soligenix, Inc. (SNGX) has a number of important catalysts ahead in the second half of 2025.The company is currently conducting the Phase 3 FLASH2 trial of HyBryte (SGX301) for the treatment of early-stage cutaneous T cell lymphoma (CTCL).We anticipate an update on enrollment in the 2H25, with topline results expected in the 2H26.

SNGX: Multiple Catalysts Upcoming in 2H25 